La catástrofe de la talidomida y su importancia en la seguridad de los medicamentos
The thalidomide catastrophe and its importance in the safety of medicines
A catástrofe da talidomida e sua importância na segurança de medicamentos
Resumen
Bibliografía
(1) Franks ME; Macpherson GR; Figg WD. Thalidomide. The Lancet. 2004;363(9423):1802-1811. https://doi.org/10.1016/S0140-6736(04)16308-3
(2) Vargesson N. Thalidomide-induced limb defects: Resolving a 50-year-old puzzle. Bioessays. 2009;31(12):1327- 1336. https://doi.org/10.1002/bies.200900103
(3) Speirs AL. Thalidomide and congenital abnormalities. The Lancet. 1962;279(7224):303-305. https://doi.org/10.1016/s0140-6736(62)91248-5
(4) Papaseit E; García-Algar O; Farré M. Talidomida: una historia inacabada. An Pediatr. 2013;78
(5):283-287. https://doi.org/10.1016/j.anpedi.2012.11.022 (5) Food and Drug Administration (FDA). FDA pregnancy categories; 2008. https://bit.ly/3uqbkIQ
(6) Botting J. Animals and medicine: The contribution of animal experiments to the control of disease. Cambridge: Open Book Publishers; 2015.
(7) Castro-Pastrana LI. Farmacovigilancia: un concepto en constante evolución. Entorno UDLAP. 2017;2:44-47. https://bit.ly/33ksbRn
(8) Food and Drug Administration (FDA). Vaccines and Related Biological Products Advisory Committee Meeting, December 10, 2020. FDA Briefing Document PfizerBioNTech COVID-19 Vaccine; 2020. https://bit.ly/3b8fahZ
(9) Food and Drug Administration (FDA). Vaccines and Related Biological Products Advisory Committee Meeting, December 17, 2020. FDA Briefing Document Moderna COVID-19 Vaccine; 2020. https://bit.ly/3h69Gs7
(10) Gee J; Marquez P; Su J; Calvert GM; Liu R; Myers T et al. First month of COVID-19 vaccine safety monitoring— United States, December 14, 2020 - January 13, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(8):283-288. http://doi.org/10.15585/mmwr.mm7008e3
(11) Bigi C; Bocci G. The key role of clinical and community health nurses in pharmacovigilance. Eur J Clin Pharmacol. 2017;73(11):1379-1387. http://doi.org/10.1007/s00228-017-2309-0
(12) Alan S; Ozturk M; Gokyildiz S; Avcibay B; Karataş Y. An evaluation of knowledge of pharmacovigilance among nurses and midwives in Turkey. Indian J Pharmacol. 2013;45(6):616-618. http://doi.org/10.4103/0253-7613.121375
(13) Giraldo-Matamoros P; Álvarez-Díaz MDM; RamosAceitero JM. Papel de la enfermería extremeña en el Sistema Español de Farmacovigilancia (2000-2005). Enferm Clín. 2007;17(6):318-321. https://doi.org/10.1016/S1130-8621(07)71824-7
(14) Conforti A; Opri S; D’Incau P; Sottosanti L; Moretti U; Ferrazin F; Leone R. Adverse drug reaction reporting by nurses: Analysis of Italian pharmacovigilance database. Pharmacoepidemiol Drug Saf. 2012;21(6):597-602. https://doi.org/10.1002/pds.3225
(15) World Health Organization (WHO). Promoting rational use of medicines: Core components. World Health Organization; 2002. https://bit.ly/2QS73PY
- Resumen visto - 598 veces
- PDF descargado - 84 veces
